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prediction of coding and regulatory structural
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Abstract
Structural variants (SVs) are implicated in the etiology of Mendelian diseases but have been systematically underascertained owing to sequencing technology limitations. Long-read sequencing enables comprehensive detection of
SVs, but approaches for prioritization of candidate SVs are needed. Structural variant Annotation and analysis (SvAnna)
assesses all classes of SVs and their intersection with transcripts and regulatory sequences, relating predicted effects
on gene function with clinical phenotype data. SvAnna places 87% of deleterious SVs in the top ten ranks. The interpretable prioritizations offered by SvAnna will facilitate the widespread adoption of long-read sequencing in diagnostic genomics. SvAnna is available at https://github.com/TheJacksonLaboratory/SvAnna.
Keywords: Long-read sequencing, Whole genome sequencing, Structural variant
Background
Structural variants (SVs) range from 50 base pairs (bp) to
megabases in size and can be classified into a wide range
of events including deletions, tandem and interspersed
duplications, insertions, inversions, translocations, or
complex combinations of these events [1]. The advent of
short-read exome sequencing in 2010 ushered in a decade of novel discoveries in Mendelian genetics and led to
the introduction of diagnostic exome and subsequently
genome sequencing. Over 100 short read-based mappers
and over 40 short-read variant callers have been introduced since 2010; while performance has been steadily
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increasing, SV calling from short reads is reported to
have a recall of between 10 and 70% associated with
high false-positive rates [2, 3]. Long-read sequencing
(LRS), including both PacBio single-molecule real-time
sequencing (SMRT) and Oxford Nanopore sequencing, produces longer reads that can be more accurately
mapped to the reference genome even in regions that are
inaccessible to short-read sequencing (SRS) [4, 5].
LRS technology can address some of the shortcomings of SRS and enable more comprehensive detection of
a broader range of SVs. A recent study with LRS in conjunction with additional methods such as single-cell template strand sequencing estimated that while 78% of SVs
identified by SRS are concordant with LRS SV calls, only
30% of LRS SVs were observed in the short-read WGS
callset; on average, 24,653 SVs were detected per genome
by LRS [6]. SRS captures the majority of SVs affecting coding sequence in genes with existing evidence for
dominant-acting pathogenic mutations from OMIM, and
the majority of SVs identified only by LRS are located in
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highly repetitive regions that have been previously inaccessible to human disease studies [7]. Initial studies have
appeared on LRS as a diagnostic tool for the diagnosis of
Mendelian disease, with reports on the detection of large
deletions, insertions, translocations, and tandem repeat
expansions [4, 8–11]. LRS can be used to address cases in
which SRS and sometimes cytogenetic or chromosomal
microarray analysis has failed to identify an etiology, and
therefore analysis may focus on intermediate size SVs
(50 bp to 2 kb) difficult to detect with the other methods [12]. The community, however, lacks dedicated tools
for prioritization of all classes of SVs identified by LRS
experiments, which hinders the utility of LRS in Mendelian disease studies.
In this work, we introduce Structural variant Annotation and analysis (SvAnna), an integrated tool for the
annotation and prioritization of SVs called in LRS data
starting from variant call format (VCF) files produced
by LRS SV callers such as pbsv, sniffles [13], and SVIM
[14]. SvAnna is freely available for academic use (https://
github.com/TheJacksonLaboratory/SvAnna)
[15].
SvAnna prioritizes variants in light of their overlap with
structural elements of genes and promoters. On a curated
set of 182 case reports of 188 SVs underlying Mendelian
disease, SvAnna placed the correct variant within the top
10 ranks (out of 62,337–107,233 variants per VCF file) in
87% of cases.

Methods
Comprehensive and harmonized representation of variants
in VCF files

SvAnna was designed to capture all classes of structural
variation represented in VCF files. VCF specification
allows three notations for storing variant coordinates,
alleles, and attributes. The variant coordinates and variant alleles can be specified using (a) default (sequence)
representation (the ALT sequence is known, the variant end position is inferred from length of the ALT
sequence), (b) symbolic representation (the ALT
sequence is not provided, e.g., <DUP>, <INV>, the end
position is reported in the INFO field), or (c) breakend
notation for complex rearrangements, where adjacencies of the novel rearrangement are described on multiple lines using the square bracket notation. We developed
a Java library called Svart [16] that decodes all three
notations and provides a consistent API for all variant
categories. Besides modeling variants, Svart standardizes representation of genomic elements, such as genes,
transcripts, enhancers, repetitive regions, and dosagesensitive regions, and handles conversion of coordinates
between genomic coordinate systems and strands, and
simplifies calculation of distances and overlaps between
the genomic elements. SvAnna leverages Svart to
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represent structural variants specified in any valid VCF
notation from both short-read and long-read VCF files in
a harmonized form for the analysis of overlap of SVs with
transcripts. For VCF records formatted in the breakend
notation (BND), SvAnna assumes that the record represents a novel adjacency between the two contigs. The
adjacencies are analyzed individually; SvAnna does not
group the adjacencies based on the EVENT INFO field.
Data sources

The input variants are filtered to remove the common SVs before the prioritization. SvAnna uses several
sources of common SVs and their frequencies: Database
of Genomic Variants [17], GnomAD SV [18], Human
Genome Structural Variation Consortium (HGSVC) SVs
freeze 3 [6], and dbSNP v151 databases (all accessed in
April 2021). Transcript definitions were generated for
RefSeq and Ensembl using Jannovar [19]. Enhancer definitions were extracted from the VISTA database [20].
Locations of repetitive elements were taken from the
UCSC Genome Database [21]. Computational disease
definitions were extracted from the Human Phenotype
Ontology [22] (HPO) resource (06/2021 release).
Variant filtering

SvAnna lets the user filter the input variants by depth of
coverage and by population frequency. The depth of coverage is reported in idiosyncratic manner depending on
the variant caller. We tested SvAnna to work with three
long read structural variant callers: pbsv, sniffles [13], and
SVIM [14] (Additional file 1: Table S1). If the required
attributes are not present, SvAnna still includes the variant in the output.
For population frequency-based filtering, we considered the variants occurring in more than 1% of the population as common. SVs called in the VCF file are removed
from the analysis if they show greater than 80% reciprocal overlap with a common variant in any of the source
databases (DGV, gnomAD-SV, dbSNP, and HGSVC SVs).
The user can adjust the frequency and reciprocal overlap
thresholds via the command line interface.
Variant prioritization

To prioritize an SV, SvAnna first determines the set of all
genes G = {g1, g2, …}—either the genes with at least one
transcript affected by the SV or the closest upstream and
downstream genes in case of an intergenic SV. SvAnna
applies different rules for the various categories of SV. For
each gene g ∈ G, a sequence deleteriousness score δ(g) is
calculated to reflect the predicted effect of the variant on
gene functionality and dosage, where δ stands for deleteriousness. The rules for calculating δ(g) differ according
to the SV type and are described in the following sections
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and summarized in Table 1. δ(g)=0 for presumed neutral
variants, with higher scores representing higher degrees
of predicted deleteriousness.
Deletions, duplications, and inversions

Scoring δ(g) for deletions and duplications depends on
the type of sequence affected. The maximal deleteriousness is scored for coding sequences. δ(g)=1 for deletions
that disrupt the sequence of a transcript by removing
the entire transcript or part of the coding sequence by
deletion of one or more exons. For untranslated regions
(UTRs), the score δ(g) for gene g is determined as a function of SV and UTR lengths as follows:


2 lenSV
,1
δ(g) = min
(1)
lenUTR
A deletion that encompasses 50% or more of the UTR
will be assigned a score of 1 (maximal deleteriousness).
Smaller deletions will receive proportionally less deleterious scores.
Analogously, a duplication that adds an entire copy of
a transcript without disrupting the coding sequence is
assigned a δ(g) score of 1 (a triplication would be assigned
a score of 2, and so on). A duplication that affects coding
sequence and/or splice site regions receives a δ(g) score
of 1; however, a tandem duplication that extends beyond
either start or end of the transcript, and thus does not
alter the primary linear transcript sequence, is regarded
as neutral (δ(g) = 0).
If a breakpoint of an inversion disrupts the coding
sequence of a transcript, it is assigned a score of 1. However, an inversion that completely contains a transcript is
assumed to be neutral, and receives a score of δ(g)=0.
Insertions

To score insertions located within the coding sequence of
a transcript, SvAnna checks if the insertion disrupts the
reading frame. Frame-shifting insertions are assigned a

δ(g) = 0.9 and the insertions that do not alter the reading
frame receive δ(g) = 0.2. If the insertion is located in the
5′ or 3′ UTR, the δ(g) score is determined as a function of
insertion and UTR length:


lenINS
,1
δ(g) = min
(2)
lenUTR
An insertion that adds the number of bases corresponding to 100% of the UTR or more will be assigned a
score of δ(g)=1. Shorter insertions receive proportionally
lower deleteriousness scores. Insertions located outside
of the coding sequence, splice site regions, promoter, and
UTRs are assigned a score of δ(g) = 0 (non-deleterious).
Translocations

Translocation breakpoints that disrupt the transcript
sequence or the promoter region are assigned a score
of δ(G)=1. The scoring process applies to both breakends
of a translocation.
Phenotype matching

SvAnna takes a list of HPO terms describing the clinical manifestations of the proband as input. It matches
them to the 7981 computational disease models of the
HPO using symmetric Resnik matching [23]. Briefly, to
calculate the Resnik symmetric matching score ɸ(Q, D)
for disease D annotated with {d1, …, dm} HPO terms and
query Q consisting of {q1, …, qn} HPO terms describing
the clinical manifestations of the proband, SvAnna uses:

φ(Q, D) =

sim(Q → D) + sim(D → Q)
2

(3)

where sim(Q → D) is a method for obtaining one-sided
semantic similarity between Q and D. The one-sided
semantic similarity is obtained as:

Table 1 Summary of rules for calculating sequence deleteriousness score δ(g)
SV class

t ⊂ SV

t ⇌ SV

SV ⊂ e
Coding or splice

DEL

1

1

{0.8, 1}

DUP

1a

0

{0.8, 1}

INV

0

1

1

INS

–

–

{0.2, 0.9}

BND

–

–

1

UTR
0 ≤ δ(g)≤1

Intronic

Promoter

0

0.4

0 ≤ δ(g)≤1

0

0.4

0 ≤ δ(g)≤1

0

0.4

0 ≤ δ(g)≤1

0

0.4

1

1

0.4

Higher scores indicate a greater degree of predicted deleterious effect on transcript function. t ⊂ SV: The SV fully contains the transcript in question. t ⇌ SV: Partial
overlap of the transcript and the SV. SV ⊂ e The SV is completely contained within the indicated sequence element. {0.8, 1} and {0.2, 0.9} indicate scores for {in-frame,
frameshift} variants
a

Duplication of the entire gene is assigned a score of 1, triplication is assigned a score of 2, and so on
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Human Phenotype Ontology terms [22, 24]. The curated
SVs included deletions, duplications, inversions, insertions, and translocations affecting a differing number
of genomic elements. The number of clinical features
ranged from 1 to 22 with a median of 5 features per case.
We recorded the case reports in the Global Alliance for
Genomics and Health (GA4GH) Phenopacket format
[25]. The phenopackets are available at Zenodo (https://
zenodo.org/record/5071267) [26].
To provide a realistic background in the performance
benchmark, we used ten VCF files with SVs generated by
PacBio long read whole genome sequencing (see below)
of peripheral blood samples obtained from ten individuals. The ten individuals are not related to 182 curated
case reports. Since all benchmarked tools evaluate each
variant independently, we used a simple strategy to simulate a variant dataset by adding disease-associated SVs
into a background VCF file derived from PacBio wholegenome sequencing (see below). We ran the benchmark
on a case basis; we added all variants of the case report
(i.e., both SVs in case of compound heterozygous genotype) in turn to one of ten background VCF files, and
we recorded the median SV rank from the ten VCF files.
We used the benchmarking schema to compare SvAnna
with AnnotSV [27], X-CNV [28], SvScore [29], and ClassifyCNV [30]. The benchmark was performed using
the pipeline engine Nextflow [31]. In our performance
benchmarks, variants whose ALT allele is supported by
< 3 reads are removed prior variant prioritization. To
ensure that the causal SV is not filtered out prior to prioritization, we set allelic depth to 5:5 when evaluating
heterozygous SV, and 0:10 when evaluating homozygous
or hemizygous SV.

1 m
maxd∈D IC(MICA(qi , d))
i=0
m
(4)
To save computational time, SvAnna pre-calculates the
information content of the most informative common
ancestor IC(MICA(t1, t2)) for all terms t used to annotate
computational disease models.
sim(Q → D) =

The PSV score

The Pathogenicity of Structural Variation (PSV) score
is calculated based on the sequence deleteriousness
score δ(g) and phenotype similarity score ɸ(Q, D) for
all affected genes G. The sequence score δ(g) for each
affected gene is weighted by the phenotypic similarity
score ɸ(Q, D).

PSV (Q, G, D) =
δ(g)· eφ(Q,D)
(5)
g∈G
Here, the PSV score is calculated as a function of the
query HPO terms (Q), the set of affected genes G, and
the Mendelian diseases D associated with the genes in G.
δ(g) is weighted by the exponentiated phenotypic similarity ɸ(Q, D) of the query terms Q to a computational
model of a disease D that is associated with variants in g.
SvAnna uses the highest ɸ(Q, D) if more than one disease
is associated with variants in g.
Performance benchmarks and comparison of with other
algorithms for ranking pathogenic SVs

We conducted a manual review of the scientific literature to create a dataset of disease-associated SVs for
benchmarking SvAnna and other tools for SV annotation and prioritization. The dataset comprised 188 disease-associated SVs from 182 case reports published in
146 articles (Table 2, Additional file 1: Fig. S1). In addition to genomic coordinates and genotypes of the causal
variants, we recorded NCBI Gene and OMIM identifiers for the causal gene and the associated disease, and
we encoded the clinical features of the proband into

AnnotSV

AnnotSV is an open source tool that annotates structural variants stored in VCF and BED format with functional, regulatory, and clinical information and classifies
SVs into five pathogenicity classes: benign, likely benign,

Table 2 Summary of curated collection of deleterious SVs
Deletions

Duplications

Inversions

Insertions

Translocations

Total

Multiple genes

7

2

4

N/A

5

18

Multiple exons

37

19

5

N/A

N/A

61

Single exon

81

16

2

3

N/A

102

Promoter

5

0

0

0

0

5

Intronic

2

0

0

0

N/A

2

Total

132

37

11

3

5

188

We curated a collection of 188 published deleterious SVs based on 182 cases published in 146 clinical case reports. We considered five classes of SVs commonly
present in LRS variant calling results: deletions, duplications, inversions, insertions, and translocations. We further classified the SVs into five functional categories
based on the number of affected genes and the relative location of the SV region with respect to transcripts of genes. The case reports are available for download
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variant of uncertain significance, likely pathogenic, and
pathogenic. AnnotSV reports results in the tabular format. We performed a local installation of AnnotSV v3.0.9
(accessed on June 25 2021). We used full annotation
mode when running AnnotSV to produce a single row per
SV in the result file, and we set the -SVminSize to 1 to
ensure SVs shorter than 50 bp (including causal SVs) are
analyzed. The tabular output reports the annotated SVs
as one SV per row, and the rows are ordered by decreasing priority. We used the row number to determine the
variant rank. If the causal variant was assigned pathogenicity class = NA instead of one of the five pathogenicity classes, and therefore missed, we assigned the variant
the rank 40,000.
SVScore

SVScore [29] is a tool for scoring structural variants by
aggregating genome-wide CADD [32] scores. The CADD
scores are aggregated in multiple ways (operations), and
reported to the output VCF file. We used UCSC’s LiftOver tool to remap the variant coordinates into GRCh37
reference genome and we ran SVScore v0.6 with the following operations: sum, max, mean, meanweighted,
top10, and top10weighted. To calculate the variant rank,
we extracted values of the SVSCOREMAX, SVSCORESUM, SVSCOREMEAN, and SVSCORETOP10 attributes from the VCF INFO field. If the value was equal to
− 1, we assigned the variant the rank 40,000.
X‑CNV

X-CNV [28] uses extreme gradient boosted trees to predict deleteriousness of deletions and duplications in the
form of meta-voting prediction (MVP) score. The MVP
score integrates several dozens of features, including SV
characteristics (type, allele frequency based on DGV,
dbVar), functional deleteriousness predictions, non-coding features (CTCF, cCREs, pELS, and dELS elements),
and genome-wide annotations. X-CNV ingests variant
coordinates in BED format and provides a CSV file with
feature values and MVP score. To benchmark X-CNV,
we used UCSC’s LiftOver tool to remap the coordinates
of deletions and duplications into GRCh37 reference
genome, and we stored the coordinates into a BED file.
We ran X-CNV (accessed on February 9 2022), and we
used the MVP score to determine the variant rank. If
the causal variant was not a deletion or duplication, and
therefore missed, we assigned the variant the rank 40,000.
ClassifyCNV

ClassifyCNV [30] is a tool that calculates numeric deleteriousness scores for deletions and duplications, and
assigns the ACMG category based on predefined score
thresholds. The tool follows the criteria of the ACMG
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scoring rubrics to assign points, and writes the overlapping dosage-sensitive genes, protein-coding genes, the
clinical classification, and the sum of points into a TSV
file. To benchmark ClassifyCNV, we converted the coordinates of deletions and duplications into BED format
and we ran ClassifyCNV v1.1.1 with default parameters.
We used the Total score to determine the variant rank.
In case of tied variant scores, the variant was ranked
as the variant located in the middle of the tied variant
group. We assigned rank 40,000 to all non-deletions and
non-duplications.
Long read sequencing

We used VCF files from ten in-house long read (PacBio)
whole genome sequencing experiments as background
files for the simulations in order to provide a realistic
background in the performance benchmark. Samples
were obtained from Ludwig Boltzmann Institute for Rare
and Undiagnosed Diseases, Vienna, Austria, the Department of Human Genetics, New York State Institute for
Basic Research in Developmental Disabilities, Staten
Island, New York, USA, and the Children’s Hospital of
Philadelphia with relevant ethical approval. The ten background VCF files are not related to the 182 case reports
used for performance benchmarks. We used a similar
strategy to assess the performance of the Exomiser tool
[33] under the assumption that a more accurate assessment of the accuracy of prioritization results can be
obtained with real rather than simulated VCF files, and
indeed the performance of Exomiser with in-house VCF
files was inferior to the performance obtained by using
VCF files from the 1000 Genomes Project Consortium as
background [34]. Currently, we are not aware of collections of publicly available long-read VCF files that could
be used for bioinformatic simulations.
High molecular weight (HMW) DNA extraction

The HMW gDNA was extracted using the Gentra Puregene (Qiagen) kit. Frozen cells or tissues were first pulverized using a mortar and pestle and transferred to a
15 mL tube that contained Qiagen Cell Lysis Solution.
The lysate was then incubated with Proteinase K for 3 h
at 55 °C, followed by RNase A for another 40 min at 37 °C.
Samples were cooled on ice, and Protein Precipitation
Solution was added. Samples were then vortexed and
centrifuged. The supernatant was transferred to a new
tube containing isopropanol for precipitation. Pellet was
washed with 70% ethanol, air dried, and rehydrated in
PacBio Elution Buffer until dissolved.
PacBio HiFi whole genome sequencing

This protocol was carried out using the PacBio SMRTbell
Express Template Prep Kit 2.0 and the SMRTbell Enzyme
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Cleanup Kit. Fifteen micrograms of DNA was sheared
to 20 kb using g-TUBE (Covaris). The sheared DNA was
purified using Ampure PB beads (PacBio). Ten micrograms of sheared DNA was used in removing single
strand overhangs, followed by DNA damage repair and
End repair/A-tailing. The repaired/modified DNA was
used for V3 adapter Ligation. The adapter ligated library
was treated with Enzyme mix for Nuclease treatment to
remove damaged or non-intact SMRTbell templates. The
purified library was then size selected using two-step
size selection with Blue Pippin (Sage Science) generating
9–13 kb and > 15 kb fractions. The size selected and purified > 15 kb fraction of the library was used for sequencing on a Sequel II device.

exons are affected and whether the transcriptional start
site of the coding sequence is disrupted.
For each class of variant, SvAnna defines rules to assess
a sequence deleteriousness score δ(G) for a set of genes
G affected by the variant (Fig. 1A). At the same time, a
phenotypic relevance score Φ(Q,D) is calculated based
on the similarity of patient phenotypes Q encoded using
Human Phenotype Ontology [22, 24] (HPO) terms and
the ~ 8000 computational disease models D of the HPO
project (Fig. 1B). The candidates are ranked based on
a PSV score that is calculated as a function of the δ(G)
and Φ(Q,D) scores. The following sections explain the
approach to specific classes of SV.

Alignment and variant calling

To calculate the priority of a deletion of a genomic region,
SvAnna determines the relative location of each overlapping gene with respect to the variant. Deletions can fully
contain a transcript, partially overlap, or be contained in
a transcript region. SvAnna assigns complete transcript
deletions a δ(g) score of 1. Deletions of single exons are
assigned a score of 1 if they include coding sequence or a
canonical splice site region and lead to shift of the reading
frame. In-frame deletions involving one or more exons
receive a score of 0.8. If a deletion is located in an intron,
it is assigned a score of 0 (not deleterious). If a deletion
affects an untranslated region (UTR), it is assigned a
score based on the length of the SV and the UTR, with
higher (more deleterious) scores being assigned to SVs
that are large compared to the UTR sequence. In some
cases, the effect of an SV is different for different transcripts of a gene. SvAnna chooses the highest transcript
score and uses that score as the δ(g) score for the gene. If
a deletion encompasses multiple genes, the δ(g) score is
assigned in this way for each gene.
For example, a ~ 6.9 kb-long deletion that leads to inframe loss of 48 amino-acid residues encoded by exon 2
of NF1 (NM_000267.3) is considered to alter the function of the gene (δ(g) = 0.8) as the deletion removes the
entire exon from the transcript [35]. Together with the
phenotype features of the proband consisting of plexiform neurofibroma (HP:0009732), spinal neurofibromas
(HP:0009735), tibial pseudarthrosis (HP:0009736), and
multiple cafe-au-lait spots (HP:0007565), the variant
attains rank 1 with a final PSV score of 157.95 (Fig. 2A).
SvAnna generates an HTML output of the variant and its
position with respect to the affected transcripts, repetitive elements, and enhancers (see Additional file 1: Fig.
S2 for this example). The median rank of 81 cases with
single exon deletions was 1.
A deletion of three exons in BRCA1 received a PSV
score of 427.0 and rank 1 (Additional file 1: Fig. S3). The
median rank of multiple-exon deletions was 1. SvAnna

We aligned long-read PacBio HiFi WGS data to the
GRCh38 (hg38) reference using pbmm2 (v1.3.0) with
--preset CCS option enabled. We identified SVs on the
indexed bam files using pbsv (v2.4.0).

Results
We developed SvAnna, a tool for phenotype-driven
annotation and prioritization of SVs detected in LRS.
SvAnna was designed to prioritize a broad range of SV
classes such as deletions, duplications, inversions, copy
number variants (CNVs), insertions, and translocations
that affect one or more genes. SvAnna filters out common SVs and calculates a numeric priority score for the
remaining rare SVs by integrating information about
genes and promoters with phenotype matching to prioritize potential disease-causing variants. SvAnna outputs
its results as a comprehensive tabular summary and as an
HTML file intended for human consumption that visualizes each variant in the context of affected transcripts,
enhancers, repeats, and dosage sensitive regions, providing information about the effects of the variant on transcripts, chromosomal locations, and Mendelian diseases
associated with the affected genes.
Pathogenicity of Structural variation (PSV) score

SvAnna assesses each variant in the context of its
genomic location. SvAnna first compares each variant
to three sources of common SVs on the basis of reciprocal overlap. In addition to Database of Genomic Variants
(DGV), gnomAD-SV, and dbSNP, which are largely based
on data from SRS, SvAnna includes a recent dataset of
SVs called by LRS (HGSVC) [6]. Common variants are
removed according to user-defined frequency and overlap constraints (Methods).
For each SV, SvAnna determines the extent of overlap
with genomic elements, including promoters and transcripts. For each transcript, it determines which exon or

Deletions and duplications

Danis et al. Genome Medicine

(2022) 14:44

Page 7 of 13

Fig. 1 Overview of SvAnna algorithm. A Sequence deleteriousness score δ(G). The score assesses deleteriousness (predicted effect on gene
function) by means of a series of heuristics for different SV classes (Table 1). B Phenotype similarity score Φ(Q,D). SvAnna calculates the phenotypic
similarity for a set of HPO terms Q representing the patient’s phenotypic features and HPO terms D for a disease. SvAnna computes the information
content (IC) of the most informative common ancestor (MICA) for all term pairs q, d for q ∈ Q and d ∈ D. The mean ICs μQ and μD are calculated for Q
and D, and the final similarity score Φ is calculated as the mean of μD and μQ. The δ(G) and the Φ(Q,D) scores are combined to obtain the final PSV
score (Methods)

uses a slightly different approach to prioritize multigene SVs. For instance, a deletion at chr2:109,923,337–
110,405,062 (hg38) affects four genes (LIMS3, MALL,
NPHP1, and MTLN). SvAnna calculates the δ(g) score of
each gene as 1, weighted by the phenotype score according to equation 5 (Methods). Only NPHP1 is associated
with a phenotypically relevant disease (Joubert syndrome
4) and its contribution to the final PSV score is highest
(Additional file 1: Fig. S4). The median rank of deletions
affecting multiple genes was 1.
Duplications are handled in a similar way to deletions
except that the gene g that is entirely spanned by a duplication is assigned a δ(g) score of 1. Similar considerations about duplications that affect individual exons or an
entire transcript pertain as with deletions. Tandem duplications that do not alter the primary linear sequence of a
transcript (e.g., a duplication of the final exon of a transcript) are assigned a score of 0 (i.e., are assumed not to
be deleterious). For example, a pathogenic duplication of
36 bp within one exon of the PIBF1 gene was assigned a
PSV score of 3.38 (Additional file 1: Fig. S5).
Inversions

An inversion is prioritized using a similar approach
to that used for evaluating a deletion, with

several differences. The δ(g) score for a genomic element
spanned by an inversion is defined as 0 (since the primary
sequence of the element is unchanged). If the sequence
of a transcript is interrupted by inversion breakends, a
δ(g) score of 1 is assigned. Additionally, inversions that
affect one or multiple (but not all) exons of a transcript
are assigned a score of 1. An inversion located completely
within an intron is assigned a score of 0 (not deleterious).
For example, breakpoints of a 12 kb copy neutral inversion identified in monozygotic twins suffering from intellectual disability disrupt genic regions of BRPF1 and
CPNE9 [36]. Since each breakpoint disrupts the gene
sequence, the δ(g) score is set to 1 for both genes. Deleterious variants in BRPF1 are associated with Intellectual
developmental disorder with dysmorphic facies and ptosis
(OMIM:617333). The final PSV score of 9.25 aggregates
scores of two disrupted genes: phenotypically relevant
BRPF1 (8.25) and disrupted, but phenotypically not relevant CPNE9 (1.0) (Figs. 2B, Additional file 1: Fig. S6).
5′UTR and transcriptional start site variants

SvAnna has specific rules for prioritizing SVs in non-coding sequences. SvAnna assumes that variants affecting
UTR regions, especially SVs, are less likely to have a functional impact on gene expression or translation. SvAnna
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Fig. 2 Prioritization of variants. A A case of proband with a single-exon deletion in the NF1 gene [35]. The deletion results in δ(g) = 0.8 for NF1. To
calculate semantic similarity Φ(Q,D) for NF1, SvAnna evaluates five computational disease models associated with variants in NF1. In case of this
proband, Neurofibromatosis, Type I (OMIM:162200) is the disease model that matches the proband’s clinical condition the best (Φ(Q,D) = 5.28). As
NF1 is the only gene affected by the deletion, δ(g) and Φ(Q,D) of NF1 are the only determinants of the final PSV score. B A case of proband with
an inversion involving 3′ end of CPNE9 and 5′ end of BRPF1 [36]. SvAnna assigns δ(g) score of 1 to both CPNE9 and BRPF1 that are disrupted by the
inversion. Unlike the case of NF1 variant, the inversion involves > 1 genes; therefore, the final PSV integrates the scores of phenotypically relevant
BRPF1 (8.25) and disrupted, but phenotypically non-relevant CPNE9 (1.00)

calculates the δ(g) score for a UTR variant as a function
of the variant length and UTR length (Methods). However, the variants that disrupt transcription start sites
(TSS) are considered just as deleterious as variants that
affect coding sequences. As an example, we evaluated de
novo deletion of 1571 bp affecting the first non-coding
exon of AMER1 [37]. The deletion was processed as a loss
of TSS, leading to a PSV score of 10.4 (Additional file 1:
Fig. S7).
Promoter variants

SvAnna extends the prioritization rules to variants in
gene promoters with a potential to change the gene
expression. The promoter regions are assumed to encompass 2 kb upstream of the TSS. To calculate the δ(g) score,
SvAnna assigns SVs in promoter regions a score that is
40% of that of an SV in a coding sequence. Effectively, this
means that only promoter variants in genes with a good
phenotype match get high priority scores. This is a limitation of the approach that could be overcome as our ability to build computational models of promoter variants
improves. If the variant affects a promoter and another

genic region (e.g., TSS, UTR), the most deleterious δ(g)
score for any of the regions is used to calculate the PSV
score. For example, a 13-bp deletion in the promoter of
the von Willebrand factor (VWF) gene in a patient with
type 1 von Willebrand disease [38] was assigned a PSV
score of 63.2 (Additional file 1: Fig. S8).
Translocations

SvAnna applies a series of rules to assess the pathogenicity of translocations. A translocation that disrupts the
coding sequence of a gene g or separates the transcription start site of g from its coding sequence is assigned a
δ(g) score of 1. The PSV score is calculated based on the
predicted effects of the translocation at both breakpoints.
For example, a translocation that disrupts the coding
sequence of SLC6A1 in a case of myoclonic-atonic epilepsy was assigned a PSV score of 4.74 (Additional file 1:
Fig. S9).
SvAnna achieves clinically relevant sensitivity

We are not aware of any other tool that specifically targets VCF data as produced by modern LRS SV callers.
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We ran SvAnna on 10 in house VCF files called with pbsv,
sniffles [13], and SVIM [14] and were able to annotate
~ 99.9% of variants (i.e., identify nature and position of
overlaps with transcripts). We are aware of only one comparable published tool for VCF-based phenotype-driven
SV prioritization: AnnotSV [27], a standalone commandline script that annotates SVs with functional, regulatory,
and clinical information to filter out neutral variants and
rank the candidate pathogenic variants, while the phenotype matching is delegated to a separate tool, Exomiser
[33]. AnnotSV is able to annotate only DEL and DUP calls
and missed INS, BND, CNV, and INV calls that were processed by SvAnna. For instance, on a VCF file called by
pbsv, AnnotSV missed 25,198 (40%) of 63,084 variants.
We additionally tested three representative tools for SV
analysis; we transformed the coordinates of CNVs found
in the ten LRS VCF files into BED format to enable comparison with SVScore, X-CNV, and ClassifyCNV. SvAnna
showed substantially superior performance to these tools
(Fig. 3).
No other tool we are aware of is able to process all SV
categories found in typical long-read VCF files as SvAnna
can.
To assess the practical utility of SvAnna and to compare performance with AnnotSV, SVScore, X-CNV, and
ClassifyCNV, we developed a simulation strategy based
on 182 curated case reports (Methods). We used 10 VCF
(62,337–107,233 variants) generated by our in-house
LRS pipeline and added the causal variant(s) to simulate
10 runs per curated case, for a total of 1,820 data sets.
Then, we prioritized the simulated variant dataset and
calculated the median rank for the causal variant across
10 runs. Overall, SvAnna placed the causal variant on the
top of all variants in 60% of cases, the causal variant was
at rank 10 or better in 87% of cases, and 91% of variants
were placed at a rank of 20 or better (Fig. 3A, B).
We further evaluated the performance on different
variant types. SvAnna showed consistent performance
for all variant types from our benchmark set. SvAnna
was confident in prioritization of deletions, duplications,
inversions, and insertions, assigning median variant rank
of 1. The breakend variants had a median variant rank
of 4. SvAnna supports prioritization of all variant types
(Fig. 3C, D). SvAnna performed consistently in cases
with both low and high numbers of HPO clinical features
(Additional file 1: Fig. S10).
SvAnna software

SvAnna presents its results both as tabular and VCF files
suitable for bioinformatics analysis as well as a visually
appealing HTML report to support clinical interpretation. The HTML report is a single page with a tabular
and graphical summary of the top 100 variants, with
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information about the variant (read counts, VCF id, position and length, and genotype if available), genes that
overlap the variant and Mendelian diseases associated
with the genes [39], and a list of all overlapping transcripts as well as the position and effect on the transcript.
A graphical display is generated for each variant (such as
those shown in Fig. 4 and Additional file 1: Figs. S2-S9)
as a scalable vector graphics (SVG) file that is embedded
directly in the HTML code. The SVG shows the SV and
its position compared to that of overlapping transcripts,
whose coding exons are shown in green and non-coding
exons in yellow. If applicable, overlapping repeats [21]
and VISTA enhancers [20] are shown as tracks beneath
the variant (Screenshot in Additional file 1: Fig. S11). The
SVGs additionally display dosage sensitive regions (haploinsufficiency and triplosensitivity) as reported by ClinGen [40]. SvAnna is made freely available for academic
use as a Java command-line application. The application
annotates a VCF file containing ~ 60,000 SVs in ~ 3 min
on a consumer laptop. The GitHub repository contains
source code, a pre-built executable, and links to detailed
instructions for use, as well as a VCF file with the eight
examples presented here and a tutorial.

Discussion
Our ability to analyze the role of SVs in Mendelian disease has lagged significantly behind as compared to our
capability to interpret single nucleotide variants and
other small variants. The reasons for this include technical difficulties in calling SVs, the relative lack of functional data on the effects of SVs on gene regulation, and
the paucity of genome-wide association studies for SVs
[1]. The advent of LRS promises to greatly improve the
detection of SVs in patient samples. PacBio LRS was
shown to be about three time more sensitive than a
SRS ensemble calling approach, with the improvement
was predominantly derived from improved detection
of repeat-associated SV classes, particularly of intermediate-sized SVs (50 bp to 2 kb), and insertions across
the SV size spectrum [41]. However, progress on many
fronts will be required to fully realize the promise of
LRS for genetic medicine, including continued technical improvements, cost reductions, better SV calling
algorithms, and more comprehensive knowledge of the
medical relevance of classes of SVs that were difficult or
impossible to ascertain with previous technologies.
Compared to the large variety of approaches available for SRS, there are very few computational methods
for assessing the relevance of SVs for rare disease [5].
Numerous algorithms, databases, and tools have been
developed to support the medical interpretation of diagnostic SRS. Although details vary from tool to tool, in
general, variant pathogenicity is assessed on the basis of
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Fig. 3 Comparison of prioritization performance of different methods for prioritization of SVs. A Median ranks of 188 deleterious SVs obtained
from simulated analysis runs. Top 5 means that the rank assigned by the tool was between 1 and 5, and so on. B Plot showing the cumulative rank
for prioritizations by SvAnna, AnnotSV, X-CNV, SvScore, and ClassifyCNV. C SvAnna assigns the best rankings to all 5 evaluated SV classes. D SvAnna
attains the best median ranks for SVs of all sizes, performing notably well in prioritization of variants involving multiple genes. In C and D, the boxes
represent distributions of the median ranks. Each box plot is defined so that the center line is at the median variant rank, the box borders mark the
25th and 75th percentiles, and the whiskers stretch to denote 1.5 times the interquartile range

variant allele population frequencies, evolutionary conservation, and functional impact prediction for missense,
splice, and regulatory variants [42–44]. Disease genes can
be prioritized based on functional and genomic data [45],

or on the basis of phenotypic similarity of patient phenotype definitions with computational disease models of
the HPO project [22, 46].
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Fig. 4 Inversion affecting BRPF1. Screenshot of the graphic generated by SvAnna for inv(chr3)(9725702; 9737931), a ∼12.23 kb inversion that
disrupts the coding sequence of the CPNE9 and BRPF1 genes observed in patient with intellectual disability with dysmorphic features [36]. The
graphic displays the relative location of the inversion (red box) with respect to individual transcripts of the affected genes. The transcripts are
drawn as boxes (exons) and lines (introns) where green represents the coding regions, and yellow the non-coding regions. In addition, the graphic
presents nearby repeat sequence loci to help with discovering variant calling artifacts, as well as interpretation of deleterious SVs that are often
flanked with repeat regions

There is a need to extend these algorithms for LRS.
SvAnna includes a number of innovations to this end.
VCF files represent SVs in multiple ways including the
default (sequence) representation and symbolic notation.
Translocations are represented as breakend calls on two
lines. SvAnna uses a harmonized computational model
of variants to represent each category of variant, which
enables it to apply a single prioritization approach to all
categories of SV. We are aware of only one previously
published tool for phenotype-driven prioritization of
SVs, AnnotSV [27]. In contrast to SvAnna, AnnotSV was
primarily designed to analyze SV events identified in SRS
and array-based experiments and only supports the analysis of deletions and duplications. SvAnna demonstrated
a substantially better overall performance than AnnotSV
in the ranking of all classes of the causal SVs. SVScore,
X-CNV, and ClassifyCNV do not include phenotype
matching into the variant scoring. Furthermore, X-CNV
and ClassifyCNV are limited to deletions and duplications. These factors may partially explain their relatively
poorer performance compared to SvAnna.
In our study, SvAnna prioritized 87% of SVs in the
first 10 ranks. The case reports were chosen from 182

publications, seven of which reported diagnostic results
from LRS [4, 10, 12, 36, 47–49]. Current published experience with LRS in a human genetic diagnostic setting is
limited, and it is too early to assess the potential advantage of LRS over SRS in diagnostic settings. Given that
LRS detects SVs in genomic regions that were difficult or
impossible to characterize by SRS, the medical relevance
of variation in these regions will need to be assessed.
SvAnna will benefit from future updates to the HPO
resource in this area.
SvAnna’s ability to predict the medical relevance of SVs
that affect presumptive enhancer sequences is limited.
We are aware of no current database with a comprehensive representation of Mendelian-disease associated SVs
in regulatory sequences, and the majority of relevant
case reports in the literature are not linked to enhancer
databases such as VISTA or FANTOM. As information
accrues in the literature about mechanisms of diseaseassociated variation in enhancer sequences, it will be
important to develop predictive models to accelerate
discoveries.
SvAnna runs in < 5 min for a typical genome on a consumer laptop (faster if computations are performed on
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multiple threads). All required data for running SvAnna
are provided as a compressed archive for download.
SvAnna is implemented as a standalone application with
no external dependencies.

Conclusions
We developed SvAnna, an interpretable method for phenotype-driven prioritization of deleterious SVs obtained
from high-throughput sequencing experiments. SvAnna
is currently the only tool for phenotype-based prioritization of SVs that is specifically designed to work with VCF
files produced by typical LRS SV callers. We are likely
to be at the beginning of a period of rapid expansion of
LRS in diagnostic settings. SvAnna will play an important
role in this process by promoting improved clinical interpretation of a range of SVs. The interpretable prioritizations provided by SvAnna will facilitate the widespread
adoption of LRS in diagnostic genomics. SvAnna is freely
available for academic use at https://github.com/TheJa
cksonLaboratory/SvAnna [15].
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